These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 33080350)

  • 1. Does chronic systemic injection of the DREADD agonists clozapine-N-oxide or Compound 21 change behavior relevant to locomotion, exploration, anxiety, and depression in male non-DREADD-expressing mice?
    Tran FH; Spears SL; Ahn KJ; Eisch AJ; Yun S
    Neurosci Lett; 2020 Nov; 739():135432. PubMed ID: 33080350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of clozapine-N-oxide and compound 21 on sleep in laboratory mice.
    Traut J; Mengual JP; Meijer EJ; McKillop LE; Alfonsa H; Hoerder-Suabedissen A; Song SH; Fehér KD; Riemann D; Molnar Z; Akerman CJ; Vyazovskiy VV; Krone LB
    Elife; 2023 Mar; 12():. PubMed ID: 36892930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of three DREADD agonists acting on Gq-DREADDs in the ventral tegmental area to alter locomotor activity in tyrosine hydroxylase:Cre male and female rats.
    Robinson HL; Nicholson KL; Shelton KL; Hamilton PJ; Banks ML
    Behav Brain Res; 2023 Oct; 455():114674. PubMed ID: 37722510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.
    Gomez JL; Bonaventura J; Lesniak W; Mathews WB; Sysa-Shah P; Rodriguez LA; Ellis RJ; Richie CT; Harvey BK; Dannals RF; Pomper MG; Bonci A; Michaelides M
    Science; 2017 Aug; 357(6350):503-507. PubMed ID: 28774929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clozapine N-Oxide Administration Produces Behavioral Effects in Long-Evans Rats: Implications for Designing DREADD Experiments.
    MacLaren DA; Browne RW; Shaw JK; Krishnan Radhakrishnan S; Khare P; España RA; Clark SD
    eNeuro; 2016; 3(5):. PubMed ID: 27822508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of DREADD agonists and administration route in a murine model of sleep enhancement.
    Ferrari LL; Ogbeide-Latario OE; Gompf HS; Anaclet C
    J Neurosci Methods; 2022 Oct; 380():109679. PubMed ID: 35914577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormalities in the composition of the gut microbiota in mice after repeated administration of DREADD ligands.
    Guo W; Wan X; Ma L; Zhang J; Hashimoto K
    Brain Res Bull; 2021 Aug; 173():66-73. PubMed ID: 34004259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice.
    Manvich DF; Webster KA; Foster SL; Farrell MS; Ritchie JC; Porter JH; Weinshenker D
    Sci Rep; 2018 Mar; 8(1):3840. PubMed ID: 29497149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-dependent reduction in cocaine-induced locomotion by Clozapine-N-Oxide in rats with a history of cocaine self-administration.
    Padovan-Hernandez Y; Knackstedt LA
    Neurosci Lett; 2018 May; 674():132-135. PubMed ID: 29571824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clozapine N-oxide, compound 21, and JHU37160 do not influence effortful reward-seeking behavior in mice.
    Aomine Y; Oyama Y; Sakurai K; Macpherson T; Ozawa T; Hikida T
    Psychopharmacology (Berl); 2024 Jan; 241(1):89-96. PubMed ID: 37792024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eye-Drops for Activation of DREADDs.
    Keenan WT; Fernandez DC; Shumway LJ; Zhao H; Hattar S
    Front Neural Circuits; 2017; 11():93. PubMed ID: 29218003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral Effects of Acute Systemic Low-Dose Clozapine in Wild-Type Rats: Implications for the Use of DREADDs in Behavioral Neuroscience.
    Ilg AK; Enkel T; Bartsch D; Bähner F
    Front Behav Neurosci; 2018; 12():173. PubMed ID: 30154702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term chemogenetic suppression of spontaneous seizures in a mouse model for temporal lobe epilepsy.
    Desloovere J; Boon P; Larsen LE; Merckx C; Goossens MG; Van den Haute C; Baekelandt V; De Bundel D; Carrette E; Delbeke J; Meurs A; Vonck K; Wadman W; Raedt R
    Epilepsia; 2019 Nov; 60(11):2314-2324. PubMed ID: 31608439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral Effect of Chemogenetic Inhibition Is Directly Related to Receptor Transduction Levels in Rhesus Monkeys.
    Upright NA; Brookshire SW; Schnebelen W; Damatac CG; Hof PR; Browning PGF; Croxson PL; Rudebeck PH; Baxter MG
    J Neurosci; 2018 Sep; 38(37):7969-7975. PubMed ID: 30082415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated chemogenetic activation of dopaminergic neurons induces reversible changes in baseline and amphetamine-induced behaviors.
    Chohan MO; Fein H; Mirro S; O'Reilly KC; Veenstra-VanderWeele J
    Psychopharmacology (Berl); 2023 Dec; 240(12):2545-2560. PubMed ID: 37594501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.
    Chen X; Choo H; Huang XP; Yang X; Stone O; Roth BL; Jin J
    ACS Chem Neurosci; 2015 Mar; 6(3):476-84. PubMed ID: 25587888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive Strategies for Chronic Manipulation of DREADD-controlled Neuronal Activity.
    Zhan J; Komal R; Keenan WT; Hattar S; Fernandez DC
    J Vis Exp; 2019 Aug; (150):. PubMed ID: 31498301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral application of clozapine-N-oxide using the micropipette-guided drug administration (MDA) method in mouse DREADD systems.
    Schalbetter SM; Mueller FS; Scarborough J; Richetto J; Weber-Stadlbauer U; Meyer U; Notter T
    Lab Anim (NY); 2021 Mar; 50(3):69-75. PubMed ID: 33619409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice.
    Jendryka M; Palchaudhuri M; Ursu D; van der Veen B; Liss B; Kätzel D; Nissen W; Pekcec A
    Sci Rep; 2019 Mar; 9(1):4522. PubMed ID: 30872749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gi-DREADD Expression in Peripheral Nerves Produces Ligand-Dependent Analgesia, as well as Ligand-Independent Functional Changes in Sensory Neurons.
    Saloman JL; Scheff NN; Snyder LM; Ross SE; Davis BM; Gold MS
    J Neurosci; 2016 Oct; 36(42):10769-10781. PubMed ID: 27798132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.